Allergy Shots for Pet Dander: Species-by-Species Evidence Guide
Allergy shots for pet dander are subcutaneous immunotherapy (SCIT) given to HUMANS sensitized to dander from cats, dogs, horses, guinea pigs, or other mammals. They are NOT veterinary products. Cytopoint, Apoquel, and veterinary ASIT are for the animal. Evidence quality varies dramatically by species: cat is FDA-standardized with strong RCTs; dog is 'poor and conflicting' per Smith 2016.
8 peer-reviewed sources
Allergy shots for pet dander treat HUMANS sensitized to pet allergens via SCIT. Cat has the strongest evidence (FDA-standardized extract, ~72% RCT symptom reduction). Dog evidence is 'poor and conflicting.' 16.5% of dog-sensitized adults may skip shots via Can f 5 testing.
The essentials
Allergy shots for pet dander are subcutaneous immunotherapy (SCIT) given to HUMANS sensitized to dander from cats, dogs, horses, guinea pigs, rabbits, or other mammals. They are NOT veterinary products. Cytopoint (Zoetis lokivetmab) and Apoquel (Zoetis oclacitinib) are products for dogs with atopic dermatitis; veterinary allergen-specific immunotherapy is injected into the pet itself — none of these address human IgE sensitization to pet dander. For atopic dermatitis in your pet, see a veterinarian. For pet dander allergy in you, this is the right page. This page covers human immunotherapy for pet dander sensitization.
The central clinical fact about 'pet dander' as an allergen category is that it encompasses at least seven distinct molecular allergen families, and the evidence quality for SCIT varies dramatically across species. Component-resolved IgE testing identifies which specific pet protein is driving symptoms — and that identification determines the treatment plan.
Cat (Felis catus): Cat-hair and cat-pelt are the ONLY FDA-standardized mammalian allergen extracts in the US — both at 10,000 BAU/mL under Greer license #308. Fel d 1, a 35–38 kDa secretoglobin, sensitizes 90–96% of cat-allergic patients (Grönlund H et al., Int Arch Allergy Immunol 2010). Cat SCIT evidence: Alvarez-Cuesta 1994 JACI (28-patient DBPC) and Varney 1997 Clin Exp Allergy (~72% symptom reduction on natural cat-room challenge). Cat SLIT drops: Alvarez-Cuesta 2007 Allergy (59% symptom reduction DBPC). Cat is the strongest-evidence pet-dander immunotherapy by a wide margin.
Dog (Canis lupus familiaris): No FDA-standardized dog extract exists — extracts are PNU-based or w/v with significant lot-to-lot variability. Seven co-dominant dog allergens; no single allergen exceeds 75% sensitization. Smith DM and Coop CA (Ann Allergy Asthma Immunol 2016;116:188–193) reviewed 17 trials and rated efficacy as 'poor and conflicting.' The key actionable finding: approximately 16.5% of dog-sensitized adults are monosensitized to Can f 5 (intact-male prostatic kallikrein, absent in female dogs and neutered males; Özuygur Ermis SS et al., Allergy 2023) and can adopt a female or neutered dog instead of SCIT (Schoos AMM et al., JACI Pract 2020 DBPC: 7/7 Can f 5-mono children zero reaction to female-dog extract). Hypoallergenic breeds do not solve dog allergy: Vredegoor JK et al. (JACI 2012;130[4]:904–9) found hypoallergenic breeds had HIGHER Can f 1 than non-hypoallergenic breeds; Nicholas CE et al. (Am J Rhinol Allergy 2011) found detectable Can f 1 in 94% of homes regardless of breed.
Horse (Equus caballus): Horse allergy is primarily occupational (equestrian workers, barn staff). Equ c 1 (lipocalin) sensitizes 50–76% of horse-allergic patients and is not FDA-standardized. Horse SCIT evidence is dominated by case series; RCT data are sparse. The lipocalin-triad cross-reactivity — Equ c 1 ↔ Fel d 4 ↔ Can f 6 (~55–67% sequence identity per Hilger C et al., JACI 2012) — means some apparent cat- or dog-allergic patients are primarily horse-sensitized.
Small mammals (guinea pig, rabbit, hamster, rat, mouse): Primarily occupational laboratory animal allergy (LAA) context. Guinea pig Cav p 1–6 panel; rabbit Ory c 1/3. LAA symptom prevalence: guinea pig ~31% of exposed workers (Aoyama K et al., Br J Ind Med 1992). No household SCIT RCTs for any small mammal. SCIT is attempted in some occupational cases but evidence is case-series only.
Curex pairs at-home IgE component testing with board-certified allergist review across the pet-dander panel — Fel d 1 / Fel d 2 / Fel d 4 / Fel d 7 for cat, Can f 1 / Can f 3 / Can f 5 for dog, plus relevant horse and small-mammal markers — to identify the specific pet protein driving symptoms and the appropriate species-specific immunotherapy strategy. For the cat- and other-species sensitizations that warrant immunotherapy, Curex then delivers that SCIT as an at-home allergy shot kit: a personalized serum sterile-compounded to USP <797>, self-administered as one weekly shot at home for $129/month, with the first dose and every dose change supervised live over Zoom by the prescribing allergist and a prescribed epinephrine auto-injector confirmed on hand — making safe at-home maintenance possible for eligible patients.
How allergy shots retrain your immune system
Pet dander allergy shots — across all species — work by the same SCIT mechanism: repeated controlled exposure to the pet allergen extract shifts the IgE response toward IgG4 blocking antibodies and T-regulatory cell tolerance. The critical species-by-species difference is extract quality and standardization, which determines how reliably the mechanism can be applied in clinical practice.
Species-Specific Component Diagnosis
Before any pet-dander SCIT, component-resolved testing identifies the specific protein driving symptoms: Fel d 1 vs Fel d 4 for cat; Can f 1 vs Can f 5 vs Can f 3 for dog; Equ c 1 for horse. This step prevents misallocating years of treatment to the wrong species.
Build-Up Phase (~26 weekly visits)
Weekly escalating injections from a starting fraction to the maintenance dose. A mandatory 30-minute post-injection observation period at every visit per Cox 2011 PP3.
Maintenance Phase (3–5 years)
For cat SCIT: targeting 1,000–4,000 BAU (FDA-standardized, predictable). For dog SCIT: allergist judgment on dose since no FDA-standardized reference exists. Every 2–4 weeks for 3–5 years.
Post-Treatment Remission
Durham 1999 NEJM: at least 4-year remission after 3-year SCIT. Post-treatment remission data are strongest for cat (FDA-standardized RCTs) and extrapolated to other pet allergens.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Treatment timeline — phase by phase
Pet-dander SCIT across all species follows the standard three-phase timeline. Year 1 requires approximately 39 in-clinic visits; Years 2–5 require 14–20 visits/year.
Weekly escalating injections during the build-up. Conventionally given in-clinic with a 30-minute observation at each visit; with Curex this build-up is self-administered at home as one weekly shot, with the first dose and every dose change supervised live over Zoom by the prescribing allergist and a prescribed epinephrine auto-injector confirmed on hand.
Year 1: approximately 39 total visits. Years 2–5: approximately 14–20 visits/year. Total course: approximately 95–119 visits.
Post-treatment remission data are strongest for cat (Durham 1999 NEJM framework). Benefits for dog and other pet allergens are extrapolated from general SCIT principles.
Efficacy by allergen — what the data shows
Pet-dander SCIT efficacy varies dramatically by species. Cat has the strongest evidence; dog is weak and conflicting; horse and small mammals are case-series-only. Component testing before committing to any pet-dander SCIT identifies the correct species and allergen target.
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youTreatment options side by side
Pet-dander-sensitized patients choose between species-specific SCIT, sublingual drops, and avoidance strategies — and increasingly between in-clinic and at-home delivery of the same SCIT. Curex delivers species-specific SCIT as a self-administered at-home weekly shot, while the Can f 5 test remains a unique cost-free alternative to dog immunotherapy for 16.5% of dog-sensitized patients.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
At-Home Cat SCIT (Curex) | |||||
Cat or Dog SLIT Drops (needle-free modality) | |||||
Dog: Female/Neutered Adoption (Can f 5-mono only) |
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
Curex's at-home allergy shot kit delivers personalized SCIT immunotherapy prescribed and overseen by a board-certified allergist at $129/month — the serum is sterile-compounded to USP <797> to the patient's component-specific pet-dander sensitization profile, you self-administer one weekly shot at home, and your first dose and every dose change are supervised live over Zoom with a prescribed epinephrine auto-injector confirmed on hand.
See if at-home shots are right for youSide effects — what to watch for
Pet-dander SCIT carries the same safety profile as all subcutaneous allergen immunotherapy, regardless of species. Mandatory 30-minute at-home observation after every injection.
Insurance coverage — what to expect
Pet-dander SCIT is covered by major commercial insurers and Medicare Part B when standard medical necessity criteria are met. For full insurer details, see /allergy-shots/cost/does-insurance-cover-allergy-shots.
Skip the insurance hassle — Curex is $129/mo flat, no insurance needed.
Start free assessmentFrequently asked questions
Are Cytopoint and Apoquel for humans with pet dander allergy?
No. Cytopoint (Zoetis lokivetmab, anti-IL-31 monoclonal antibody) and Apoquel (Zoetis oclacitinib, JAK inhibitor) are veterinary drugs for treating canine atopic dermatitis — the dog's own skin allergy. Neither product addresses human IgE sensitization to pet dander. They are prescribed by veterinarians, administered to dogs, and have no human indication. They appear in consumer searches for 'pet dander allergy shots' because veterinary and human-health search results overlap for pet-related queries. For HUMAN allergy to pet dander, the relevant treatments are SCIT or SLIT drops administered by a board-certified allergist.
Is cat SCIT evidence stronger than dog SCIT evidence?
Yes — substantially. Cat-hair and cat-pelt are the only FDA-standardized mammalian extracts in the US (10,000 BAU/mL, Greer license #308), enabling predictable therapeutic dosing. Cat SCIT has two rigorous DBPC RCTs: Alvarez-Cuesta 1994 JACI (28 patients, significant improvement vs placebo) and Varney 1997 Clin Exp Allergy (28 patients, ~72% symptom reduction on natural cat-room challenge). Cat SLIT drops also have DBPC RCT support (Alvarez-Cuesta 2007 Allergy: 59% symptom reduction). Dog SCIT uses non-standardized PNU-based or w/v extracts; Smith DM and Coop CA (Ann Allergy Asthma Immunol 2016) reviewed 17 dog SCIT trials and rated the evidence as 'poor and conflicting.' This asymmetry is clinically significant and patients deserve to know it.
Can component testing replace allergy shots for dog allergy?
For Can f 5-monosensitized patients — approximately 16.5% of dog-sensitized adults — component testing can reveal that immunotherapy is unnecessary. Can f 5 is a prostatic kallikrein produced only in intact male dogs; female dogs and neutered males produce none. Schoos AMM et al. (JACI Pract 2020;8:1592–1597) confirmed in a DBPC challenge that 7 of 7 Can f 5-monosensitized children had zero reaction to female-dog extract. If your component test shows IgE to Can f 5 only (with low or negative Can f 1, Can f 2, Can f 3), you can adopt a female or neutered dog and skip immunotherapy entirely. For the remaining ~83.5% of dog-sensitized patients who have broader sensitization, component testing improves — but does not replace — the need for immunotherapy if they wish to remain in contact with dogs.
What pet dander is hardest to treat with allergy shots?
Dog dander has the weakest SCIT evidence of any commonly encountered pet allergen. The fundamental problem is structural: dog allergen extracts are not FDA-standardized, no single dog allergen exceeds 75% sensitization, and 17 clinical trials reviewed by Smith 2016 yielded 'poor and conflicting results of clinical efficacy.' This is compounded by the fact that Can f 5 (intact-male prostatic kallikrein) may not be present in commercial dog extracts — causing false-negative diagnostics and ineffective immunotherapy even in patients with detectable Can f 5 IgE (Özuygur Ermis 2023). Small-mammal allergens (guinea pig, rabbit, hamster) have even less RCT evidence — only case series in occupational LAA contexts. Cat remains the most tractable pet dander allergen for immunotherapy, with FDA-standardized extract and DBPC RCTs to anchor the evidence.
Can I get allergy shots for both cat and dog dander?
Yes. A multi-allergen SCIT vial containing both cat and dog extract components can be formulated by a board-certified allergist. The clinical caveat is that adding multiple allergens to a single vial may dilute individual components below therapeutic levels — the Cox 2011 PP3 addresses allergen mixing protocols to mitigate this. Component-resolved testing for both Fel d 1 (cat) and Can f 1/Can f 5 (dog) should precede multi-allergen immunotherapy planning to confirm that both species represent clinically meaningful sensitization drivers. Patients who are Can f 5-monosensitized for dog may be better served by a cat-only SCIT regimen plus female-dog adoption rather than a multi-allergen vial.
How prevalent is pet dander allergy in the US?
NHANES 2005–2006 (Salo PM et al., JACI 2014;134:350–359) found that up to 15.7% of Americans ≥6 years report allergic reactions to cats and dogs, and 44.6% of Americans ≥6 years have detectable allergen-specific IgE to at least one allergen. Fel d 1 (cat) is detected in 99.9% of US homes including cat-free homes at approximately 1.0 µg/g geometric mean — meaning cat allergen ubiquity is nearly universal in the US regardless of pet ownership. Can f 1 (dog) is detectable in 94% of homes (Nicholas CE et al., Am J Rhinol Allergy 2011). This pervasive environmental presence is why avoidance alone is rarely effective and immunotherapy remains the disease-modifying option.
Related Articles
One-Time Allergy Shot: Steroids vs. SCIT | Curex
SCIT is never a one-time procedure. Learn what 'one-time allergy shot' actually means — Kenalog, Depo-Medrol, Xolair, or epinephrine — and why none modify disease.
Read moreCat Allergy Vaccine Explained | Curex SCIT Guide
Cat allergy vaccine means three different things. SCIT uses FDA-standardized Fel d 1 extract for ~72% symptom relief. No one-shot cure exists.
Read moreAllergy Shots for Cat Allergy | Full SCIT Guide | Curex
Allergy shots for cat allergies reduce symptoms 60-72% at the 15 mcg Fel d 1 maintenance dose. Cat SCIT efficacy, dosing, and alternatives.
Read moreAllergy Shot for Dog Allergies | Curex Human SCIT Guide
Yes, there is an allergy shot for humans allergic to dogs — but dog SCIT evidence is 'poor and conflicting.' 16.5% of patients may skip shots if Can f 5-monosensitized.
Read moreCluster Allergy Shots: Schedule & Safety | Curex
Cluster allergy shots reach maintenance in 4–8 weeks vs 6 months. Schedule, the 3× higher per-injection reaction rate, and who qualifies (Tabar 2005).
Read moreCat Allergy Shots for Humans | Curex SCIT Guide
Cat allergy shots use FDA-standardized Fel d 1 extract for ~72% symptom relief. RCT evidence, schedule, plus at-home SCIT from Curex at $129/mo.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.